Loading...
•
Dec 31, 2025
uniQure Q4 2025 Earnings Report
uniQure reported fourth quarter 2025 results with modest revenue and a quarterly net loss while maintaining a strong cash position.
Key Takeaways
uniQure generated approximately $5570000 in revenue in Q4 2025 and reported a net loss of approximately $32032000 as it continued advancing its gene therapy pipeline, including AMT-130, while ending the year with $622500000 in cash and investment securities.
Estimated Q4 revenue was approximately $5570000 based on full-year disclosures.
Quarterly net loss was approximately $32032000.
FDA recommended a randomized controlled study for AMT-130.
Cash and investment securities totaled $622500000 at year-end.
Revenue by Segment
Forward Guidance
The company expects its existing cash, cash equivalents and investment securities to fund operations into the second half of 2029.
Positive Outlook
- Cash runway projected into the second half of 2029.
- Completed follow-on offerings raising $404200000 net proceeds in 2025.
- Refinanced $50000000 debt extending maturity to October 2030.
- Additional $100000000 term loan tranche available upon regulatory milestone.
- Strong balance sheet to support pipeline advancement.
Challenges Ahead
- FDA did not agree that Phase I/II data alone support approval for AMT-130.
- Recommendation to conduct randomized, sham-controlled study.
- Enrollment paused in AMT-162 study.
- Dose-limiting toxicities observed in AMT-191 mid-dose cohort.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...